Perspective Therapeutics, Inc. — Director's Dealing 2021

Mar 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Isoray, Inc. (ISR)
CIK: 0000728387
Period of Report: 2021-03-12

Reporting Person: Woods Lori A (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-12	Common Stock	M	25000	$0.6050	Acquired	635500	Indirect
2021-03-12	Common Stock	M	62500	$0.46	Acquired	698000	Indirect
2021-03-12	Common Stock	M	62500	$0.43	Acquired	760500	Indirect
2021-03-12	Common Stock	M	62500	$0.61	Acquired	823000	Indirect
2021-03-12	Common Stock	X	24038	$0.57	Acquired	847038	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-12	Stock Options (right to buy)	$0.6050	M	25000	Disposed	2027-06-27	Common Stock (25000)	Direct
2021-03-12	Stock Options (right to buy)	$0.46	M	62500	Disposed	2028-06-13	Common Stock (62500)	Direct
2021-03-12	Stock Options (right to buy)	$0.43	M	62500	Disposed	2029-06-18	Common Stock (62500)	Direct
2021-03-12	Stock Options (right to buy)	$0.61	M	62500	Disposed	2030-06-23	Common Stock (62500)	Direct
2021-03-12	Warrant (right to buy)	$0.57	X	24038	Disposed	2025-10-22	Common Stock (24038)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	48076	Direct

Footnotes

F1: 100,000 stock options were granted on 6/27/2017. 25% vested on 6/27/2017, 25% vested on 6/27/2018, 25% vested on 6/27/2019 and the remaining 25% vested on 6/27/2020. The shares exercised on 3/12/2021 represent the shares that vested on 6/27/2020.

F2: 250,000 stock options were granted on 6/13/2018. 25% vested on 12/13/2018, 25% vested on 6/13/2019, 25% vested on 6/13/2020 and the remaining 25% will vest on 6/13/2021. The shares exercised on 3/12/2021 represent the shares that vested on 6/13/2020.

F3: 250,000 stock options were granted on 6/18/2019. 25% vested on 6/18/2019, 25% vested on 6/18/2020 and the remaining 50% will vest over the next two (2) years, commencing on 6/18/2021, until fully vested. The shares exercised on 3/12/2021 represent the shares that vested on 6/18/2020.

F4: 250,000 stock options were granted on 6/23/2020. 25% vested on 6/23/2020 and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested. The shares exercised on 3/12/2021 represent the shares that vested on 6/23/2020.

F5: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. This transaction represents an exercise for all of the warrants purchased as part of the public offering that closed on October 22, 2020.